Concepedia

Author

M. Diago

Hospital General Universitario De ValenciaORCID

Also Known As

Diago, M., Diago,Moisés, Hailemichael Desalegn, M DIAGO, M Diago, M. DIAGO, M. Diago, MOISES DIAGO, MOISÉS DIAGO, Miguel Jiménez

291

Publications

21.6K

Citations

46

H-Index

73

Concepts

All Affiliations

Hospital General Universitario De ValenciaHospital Universitario Virgen del RocíoHospital Universitario de ValmeCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y DigestivasHospital Universitario Puerta de Hierro Majadahonda
MD

About

M. Diago is an author at Hospital General Universitario De Valencia specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

30

53

8.6K

2

Health Sciences

6

6

3.8K

3

Epidemiology

6

6

493

4

Diabetes

4

4

1K

5

Public Health

3

3

2.4K

M. Diago

×

98

Publications

20.8K

Citations

45

H-Index

YearCitations

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

Michael Fried, Mitchell L. Shiffman, K. Rajender Reddy,

New England Journal of Medicine

2002

6.4K

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

Eduardo Vilar‐Gómez, Yadina Martínez-Pérez, Luis Calzadilla Bertot,

Gastroenterology

2015

2.3K

Telaprevir for Retreatment of HCV Infection

Stefan Zeuzem, Pietro Andreoné, Stanislas Pol,

New England Journal of Medicine

2011

1.5K

Peginterferon Alfa-2a in Patients with Chronic Hepatitis C

Stefan Zeuzem, S.V. Feinman, J. Rasenack,

New England Journal of Medicine

2000

1.2K

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba,

The Lancet

2019

1.2K

Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B

Patrick Marcellin, George Lau, Ferruccio Bonino,

New England Journal of Medicine

2004

1.1K

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients

Manuel Romero‐Gómez, María del Mar Viloria, Raúl J. Andrade,

Gastroenterology

2005

730

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin

Peter Ferenci, Michael Fried, Mitchell L. Shiffman,

Journal of Hepatology

2005

517

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue,

Journal of Hepatology

2020

438

Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment

José M. Sánchez–Tapias, M. Diago, P Escartín,

Gastroenterology

2006

360

Page 1